Log In
BCIQ
Print this Print this
 

TCN-202

Also known as: TCN202

  Manage Alerts
Collapse Summary General Information
Company Theraclone Sciences Inc.
DescriptionHuman mAb that recognizes a broadly conserved functional epitope on human cytomegalovirus (CMV)
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV) infection; Treat cytomegalovirus (CMV) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today